Fcγ receptors as regulators of immune responses

Nature Reviews Immunology

Volumn 8, Issue 1, 2008, Pages 34-47

  Nimmerjahn, Falk ^a   Ravetch, Jeffrey V ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; EFFECTOR CELL; GLYCOSYLATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; ANIMAL; HUMAN; IMMUNITY; IMMUNOLOGY;

ANIMALS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; RECEPTORS, FC;

EID: 37549036732     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2206     Document Type: Review

References (136)

1. Ravetch, J. V. & Lanier, L. L. Immune inhibitory receptors. Science 290, 84-89 (2000).
2. Nimmerjahn, F. Activating and inhibitory FcγRs in autoimmune disorders. Springer Semin. Immunopathol. 28, 305-319 (2006).
3. Bolland, S. & Ravetch, J. V. Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149-177 (1999).
4. Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors: old friends and new family members. Immunity 24, 19-28 (2006).
5. Ravetch, J. V. in Fundamental Immunology (ed. Paul, W. E.) 685-700 (Lippincott-Raven, Philadelphia, 2003).
6. Dijstelbloem, H. M., van de Winkel, J. G. & Kallenberg, C. G. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22, 510-516 (2001).
7. Nimmerjahn, F., Bruhns, P., Horiuchi, K. & Ravetch, J. V. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41-51 (2005). This study identifies FcγRIV as a functional activating FcR that is responsible for mediating the activity of IgG2a and IgG2b antibody subclasses in vivo.
8. Anderson, C. L. & Grey, H. M. Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J. Exp. Med. 139, 1175-1188 (1974).
9. Leclerc, J. C., Plater, C. & Fridman, W. H. The role of the Fc receptor (FcR) of thymus-derived lymphocytes. I. Presence of FcR on cytotoxic lymphocytes and absence of direct role in cytotoxicity. Eur. J. Immunol. 7, 543-548 (1977).
10. Stout, R. D. & Herzenberg, L. A. The Fc receptor on thymus-derived lymphocytes. I. Detection of a subpopulation of murine T lymphocytes bearing the Fc receptor. J. Exp. Med. 142, 611-621 (1975).
11. Takai, T. Roles of Fc receptors in autoimmunity. Nature Rev. Immunol. 2, 580-592 (2002).
12. Hulett, M. D. & Hogarth, P. M. Molecular basis of Fc receptor function. Adv. Immunol. 57, 1-127 (1994).
13. Galli, S. J. et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu. Rev. Immunol. 23, 749-786 (2005).
14. Gould, H. J. et al. The biology of IgE and the basis of allergic disease. Annu. Rev. Immunol. 21, 579-628 (2003).
15. Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
16. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. & Tedder, T. F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203, 743-753 (2006).
17. Garman, S. C., Kinet, J. P. & Jardetzky, T. S. Crystal structure of the human high-affinity IgE receptor. Cell 95, 951-961 (1998).
18. Maxwell, K. F. et al. Crystal structure of the human leukocyte Fc receptor, Fc γRIIa. Nature Struct. Biol. 6, 437-442 (1999).
19. Sondermann, P., Huber, R. & Jacob, U. Crystal structure of the soluble form of the human Fcγ-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J. 18, 1095-1103 (1999).
20. Sondermann, P., Kaiser, J. & Jacob, U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309, 737-749 (2001).
21. Radaev, S. & Sun, P. Recognition of immunoglobulins by Fcγ receptors. Mol. Immunol. 38, 1073-1083 (2002).
22. Allen, J. M. & Seed, B. Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science 243, 378-381 (1989).
23. Corper, A. L. et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nature Struct. Biol. 4, 374-381 (1997).
24. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20, 2361-2370 (1981).
25. DeLano, W. L., Ultsch, M. H., de Vos, A. M. & Wells, J. A. Convergent solutions to binding at a protein-protein interface. Science 287, 1279-1283 (2000).
26. Harris, L. J. et al. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature 360, 369-372 (1992).
27. Martin, W. L., West, A. P., Jr., Gan, L. & Bjorkman, P. J. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell 7, 867-877 (2001).
28. Saphire, E. O. et al. Contrasting IgG structures reveal extreme asymmetry and flexibility. J. Mol. Biol. 319, 9-18 (2002).
29. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
30. Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C. & Sun, P. D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem. 276, 16469-16477 (2001).
31. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406, 267-273 (2000). By generating a crystal structure of human FcγRIIIA in complex with human IgG1, the authors of this study provide fascinating insights into the antibody-FcR interaction on an atomic level; see also reference 30.
32. Kato, K., Fridman, W. H., Arata, Y. & Sautes-Fridman, C. A conformational change in the Fc precludes the binding of two Fcγ receptor molecules to one IgG. Immunol. Today 21, 310-312 (2000).
33. Zhang, Y. et al. Crystal structure of the extracellular domain of a human FcγRIII. Immunity 13, 387-395 (2000).
34. Kinet, J. P. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu. Rev. Immunol. 17, 931-972 (1999).
35. Ghazizadeh, S., Bolen, J. B. & Fleit, H. B. Physical and functional association of Src-related protein tyrosine kinases with FcγRII in monocytic THP-1 cells. J. Biol. Chem. 269, 8878-8884 (1994).
36. Wang, A. V., Scholl, P. R. & Geha, R. S. Physical and functional association of the high affinity immunoglobulin G receptor (FcγRI) with the kinases Hck and Lyn. J. Exp. Med. 180, 1165-1170 (1994).
37. Kiener, P. A. et al. Cross-linking of Fcγ receptor I (FcγRI) and receptor II (FcγRII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J. Biol. Chem. 268, 24442-24448 (1993).
38. 2+]i flux by distinct regions of an Fc receptor. Science 254, 1785-1788 (1991).
39. Rankin, B. M., Yocum, S. A., Mittler, R. S. & Kiener, P. A. Stimulation of tyrosine phosphorylation and calcium mobilization by Fcγ receptor cross-linking. Regulation by the phosphotyrosine phosphatase CD45. J. Immunol. 150, 605-616 (1993).
40. Liao, F., Shin, H. S. & Rhee, S. G. Tyrosine phosphorylation of phospholipase C-γ 1 induced by cross-linking of the high-affinity or low-affinity Fc receptor for IgG in U937 cells. Proc. Natl Acad. Sci. USA 89, 3659-3663 (1992).
41. Takai, T., Li, M., Sylvestre, D., Clynes, R. & Ravetch, J. V. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76, 519-529 (1994). By generating the γ-chain knockout mouse these authors show the central importance of this molecule for the function of activating FcRs.
42. Clynes, R. & Ravetch, J. V. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3, 21-26 (1995).
43. Park, S. Y. et al. Resistance of Fc receptor-deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102, 1229-1238 (1998).
44. Sylvestre, D. L. & Ravetch, J. V. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 265, 1095-1098 (1994).
45. Zhang, M. et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res. 64, 5825-5829 (2004).
46. Azeredo da Silveira, S. et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J. Exp. Med. 195, 665-672 (2002).
47. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789-797 (2006).
48. Nimmerjahn, F. & Ravetch, J. V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204, 11-15 (2007).
49. Ravetch, J. V. & Clynes, R. A. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16, 421-432 (1998).
50. Sylvestre, D. et al. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J. Exp. Med. 184, 2385-2392 (1996).
51. Uchida, J. et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669 (2004).
52. Kumar, V. et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J. Clin. Invest. 116, 512-520 (2006).
53. Schmidt, R. E. & Gessner, J. E. Fc receptors and their interaction with complement in autoimmunity. Immunol. Lett. 100, 56-67 (2005).
54. Barnes, N. et al. FcγRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16, 379-389 (2002).
55. Bevaart, L. et al. Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumour cytotoxicity. Br. J. Haematol. 132, 317-325 (2006).
56. Fossati-Jimack, L. et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. J. Exp. Med. 191, 1293-1302 (2000).
57. Ioan-Facsinay, A. et al. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16, 391-402 (2002).
58. Hazenbos, W. L. et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity 5, 181-188 (1996).
59. Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157-168 (2002).
60. Meyer, D. et al. FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92, 3997-4002 (1998).
61. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
62. Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J. & Levy, R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717-4724 (2004).
63. Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003). References 61-63 demonstrate the importance of FcγRs as effector molecules for antibody therapy of cancer in humans.
64. Bussel, J. B. Fc receptor blockade and immune thrombocytopenic purpura. Semin. Hematol. 37, 261-266 (2000).
65. Stuart, L. M. & Ezekowitz, R. A. Phagocytosis: elegant complexity. Immunity 22, 539-550 (2005).
66. Swanson, J. A. & Hoppe, A. D. The coordination of signaling during Fc receptor-mediated phagocytosis. J. Leukoc. Biol. 76, 1093-1103 (2004).
67. Regnault, A. et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999).
68. Goodnow, C. C., Sprent, J., de St Groth, B. F. & Vinuesa, C. G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435, 590-597 (2005).
69. Amigorena, S. et al. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256, 1808-1812 (1992).
70. Muta, T. et al. A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. Nature 369, 340 (1994). This study, together with reference 69, was the first to identify and characterize the function of the ITIMs in FcγRIIB.
71. Nitschke, L. & Tsubata, T. Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol. 25, 543-550 (2004).
72. Ono, M., Bolland, S., Tempst, P. & Ravetch, J. V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB. Nature 383, 263-266 (1996).
73. Ono, M. et al. Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signalling. Cell 90, 293-301 (1997).
74. Pearse, R. N. et al. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity 10, 753-760 (1999).
75. Tzeng, S. J., Bolland, S., Inabe, K., Kurosaki, T. & Pierce, S. K. The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl-family kinase dependent pathway. J. Biol. Chem. 22, 22 (2005).
76. Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nature Rev. Immunol. 6, 741-750 (2006).
77. Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614-1621 (2005).
78. Ravetch, J. V. & Nussenzweig, M. Killing some to make way for others. Nature Immunol. 8, 337-339 (2007).
79. Xiang, Z. et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nature Immunol. 8, 419-429 (2007). The authors demonstrate that plasma cells are susceptible to FcγRIIB-triggered apoptosis; by contrast, plasma cells from autoimmune mice were more resistant, which might explain their higher abundance in these strains.
80. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111 (2007).
81. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001). This is one of the first studies demonstrating that DCs can functionally inactivate antigen-specific T cells under steady state conditions in vivo.
82. Hawiger, D., Masilamani, R. F., Bettelli, E., Kuchroo, V. K. & Nussenzweig, M. C. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20, 695-705 (2004).
83. Kretschmer, K. et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nature Immunol. 6, 1219-1227 (2005).
84. Steinman, R. M. et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. 987, 15-25 (2003).
85. Schuurhuis, D. H., Fu, N., Ossendorp, F. & Melief, C. J. Ins and outs of dendritic cells. Int. Arch. Allergy Immunol. 140, 53-72 (2006).
86. Woelbing, F. et al. Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity. J. Exp. Med. 203, 177-188 (2006).
87. Dhodapkar, K. M., Krasovsky, J., Williamson, B. & Dhodapkar, M. V. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195, 125-133 (2002).
88. Groh, V. et al. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc. Natl Acad. Sci. USA 102, 6461-6466 (2005).
89. Rafiq, K., Bergtold, A. & Clynes, R. Immune complexmediated antigen presentation induces tumor immunity. J. Clin. Invest. 110, 71-79 (2002).
90. Schuurhuis, D. H. et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J. Immunol. 176, 4573-4580 (2006).
91. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23, 503-514 (2005).
92. Kalergis, A. M. & Ravetch, J. V. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med. 195, 1653-1659 (2002).
93. Boruchov, A. M. et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914-2923 (2005).
94. Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910-2915 (2005). References 92-94 demonstrate the important role of FcγRIIB as a regulator of DC activity and its potential to modulate adaptive immune responses.
95. Nimmerjahn, F. & Ravetch, J. V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19, 239-245 (2007).
96. Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 4005-4010 (2006).
97. Shields, R. L. et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276, 6591-6604 (2001).
98. Clynes, R. et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189, 179-185 (1999).
99. Yuasa, T. et al. Deletion of fcγ receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189, 187-194 (1999).
100. Bergtold, A., Gavhane, A., D'Agati, V., Madaio, M. & Clynes, R. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J. Immunol. 177, 7287-7295 (2006).
101. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
102. Ferrara, C., Stuart, F., Sondermann, P., Brunker, P. & Umana, P. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to nonfucosylated IgG glycoforms. J. Biol. Chem. 281, 5032-5036 (2006). This study suggests that the differential impact of fucose on binding to different Fcγ-receptors is dependent on FcγR glycosylation.
103. Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
104. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473 (2003).
105. Arnold, J. N., Dwek, R. A., Rudd, P. M. & Sim, R. B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 106, 103-110 (2006).
106. Bond, A., Cooke, A. & Hay, F. C. Glycosylation of IgG, immune complexes and IgG subclasses in the MRLlpr/lpr mouse model of rheumatoid arthritis. Eur. J. Immunol. 20, 2229-2233 (1990).
107. Mizuochi, T., Hamako, J., Nose, M. & Titani, K. Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice. J. Immunol. 145, 1794-1798 (1990).
108. Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Med. 1, 237-243 (1995).
109. Nimmerjahn, F., Anthony, R. M. & Ravetch, J. V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl Acad. Sci. USA 104, 8433-8437 (2007).
110. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006). The authors demonstrate that the sialic-acid-rich fraction of IVIG is responsible for its antiinflammatory activity.
111. Bruhns, P., Samuelsson, A., Pollard, J. W. & Ravetch, J. V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573-581 (2003).
112. Debre, M. et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993). This was the first study to show that the IgG Fcfragment is responsible for mediating the antiinflammatory activity of IVIG in human patients.
113. Samuelsson, A., Towers, T. L. & Ravetch, J. V. Antiinflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001).
114. Park-Min, K. H. et al. FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity 26, 67-78 (2007).
115. Siragam, V. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc γ receptors on dendritic cells. Nature Med. 12, 688-692 (2006).
116. McGaha, T. L., Sorrentino, B. & Ravetch, J. V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590-593 (2005). This study demonstrates the therapeutic potential of increasing FcγRIIB expression on B cells to restore tolerance in autoimmune-prone mouse strains.
117. Vitetta, E. S. & Ghetie, V. F. Immunology. Considering therapeutic antibodies. Science 313, 308-309 (2006).
118. Li, M., Wirthmueller, U. & Ravetch, J. V. Reconstitution of human FcγRIII cell type specificity in transgenic mice. J. Exp. Med. 183, 1259-1263 (1996).
119. Bolland, S. & Ravetch, J. V. Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13, 277-285 (2000).
120. -/- mice. J. Exp. Med. 195, 1167-1174 (2002).
121. + anti-DNA plasma cells. Nature Immunol. 6, 99-106 (2005).
122. Takai, T., Ono, M., Hikida, M., Ohmori, H. & Ravetch, J. V. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379, 346-349 (1996). This study describes the generation of the Fcgriib-knockout mouse, which provided the first clear evidence of the importance of this protein in regulating immune responses.
123. Paul, E., Nelde, A., Verschoor, A. & Carroll, M. C. Follicular exclusion of autoreactive B cells requires FcγRIIb. Int. Immunol. 19, 365-373 (2007).
124. Nakamura, A. et al. Fcγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191, 899-906 (2000).
125. Jiang, Y. et al. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51, 429-435 (2000).
126. Jiang, Y. et al. Genetically determined aberrant downregulation of FcγRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int. Immunol. 11, 1685-1691 (1999).
127. Pritchard, N. R. et al. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcγRII. Curr. Biol. 10, 227-230 (2000).
128. Xiu, Y. et al. Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J. Immunol. 169, 4340-4346 (2002).
129. Holmes, M. C. & Burnet, F. M. The natural history of autoimmune disease in Nzb mice. A comparison with the pattern of human autoimmune manifestations. Ann. Intern. Med. 59, 265-276 (1963).
130. Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577-1584 (2004).
131. Blank, M. C. et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 117, 220-227 (2005).
132. Su, K. et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcγRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J. Immunol. 172, 7192-7199 (2004).
133. Su, K. et al. A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcγRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J. Immunol. 172, 7186-7191 (2004).
134. Floto, R. A. et al. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nature Med. 11, 1056-1058 (2005).
135. Kono, H. et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14, 2881-2892 (2005). In references 134 and 135, the authors elegantly demonstrate that the FcγRIIB I232T allele which is associated with systemic lupus erythematosus in humans is functionally impaired owing to its inefficient association with lipid rafts.
136. Mackay, M. et al. Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157-2164 (2006).